The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot clinical trial of p53/p16-independent epigenetic therapy for pancreatic ductal adenocarcinoma (PDA).
 
Davendra Sohal
Honoraria - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine
Consulting or Advisory Role - Ability Pharma; Ability Pharma; Ability Pharma; Ability Pharma; Perthera; Perthera; Perthera; Perthera
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst)
 
Smitha S. Krishnamurthi
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst)
 
Rita Tohme
No Relationships to Disclose
 
Dale Randall Shepard
Consulting or Advisory Role - Lilly; Lilly; Lilly; Lilly; Sanofi; Sanofi; Sanofi; Sanofi
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); GITR (Inst); GITR (Inst); GITR (Inst); GITR (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Kinex (Inst); Kinex (Inst); Kinex (Inst); Kinex (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); VBL Therapeutics (Inst); VBL Therapeutics (Inst); VBL Therapeutics (Inst); VBL Therapeutics (Inst)
 
Alok A. Khorana
Honoraria - AngioDynamics; AngioDynamics; AngioDynamics; AngioDynamics; Bayer; Bayer; Bayer; Bayer; Halozyme; Halozyme; Halozyme; Halozyme; Janssen; Janssen; Janssen; Janssen; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Halozyme; Halozyme; Halozyme; Halozyme; Janssen; Janssen; Janssen; Janssen; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Seagen; Seagen; Seagen; Seagen
Research Funding - Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Leap Oncology (Inst); Leap Oncology (Inst); Leap Oncology (Inst); Leap Oncology (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Janssen; Pfizer; Pfizer; Pfizer; Pfizer
 
Yogen Saunthararajah
Stock and Other Ownership Interests - Acceleron Pharma; Acceleron Pharma; Acceleron Pharma; Acceleron Pharma; Celgene; Celgene; Celgene; Celgene; EpiDestiny; EpiDestiny; EpiDestiny; EpiDestiny
Consulting or Advisory Role - EpiDestiny; EpiDestiny; EpiDestiny; EpiDestiny
Patents, Royalties, Other Intellectual Property - -Patents around tetrahydrouridine and decitabine licensed to EpiDestiny. - Unpaid consultancy for EpiDestiny.; -Patents around tetrahydrouridine and decitabine licensed to EpiDestiny. - Unpaid consultancy for EpiDestiny.; -Patents around tetrahydrouridine and decitabine licensed to EpiDestiny. - Unpaid consultancy for EpiDestiny.; -Patents around tetrahydrouridine and decitabine licensed to EpiDestiny. - Unpaid consultancy for EpiDestiny.